Brilacidin: Phase IIb start

Next month, Cellceutix will begin a double-blind, U.S. Phase IIb trial to compare brilacidin vs. Cubicin daptomycin in about 200-215 patients with ABSSSI. The company plans to pursue an expedited reg...